Literature DB >> 20380564

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

John G Evans-Jones1, Lucy E Cottle, David J Back, Sara Gibbons, Nicholas J Beeching, Peter B Carey, Saye H Khoo.   

Abstract

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20380564     DOI： 10.1086/652149

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  28 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

2.  Older HIV-infected adults. Complex patients (III): Polypharmacy.

Authors:  Samuel F Freedman; Carrie Johnston; John J Faragon; Eugenia L Siegler; Tessa Del Carmen
Journal:  Eur Geriatr Med       Date:  2018-12-06       Impact factor: 1.710

3.  Antiretroviral Stewardship in a Pediatric HIV Clinic: Development, Implementation and Improved Clinical Outcomes.

Authors:  Alice J Hsu; Asha Neptune; Constants Adams; Nancy Hutton; Allison L Agwu
Journal:  Pediatr Infect Dis J       Date:  2016-06       Impact factor: 2.129

Review 4.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

Review 5.  Managing drug interactions in HIV-infected adults with comorbid illness.

Authors:  Christine A Hughes; Alice Tseng; Ryan Cooper
Journal:  CMAJ       Date:  2014-09-15       Impact factor: 8.262

6.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

7.  Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Authors:  Catia Marzolini; Rajith Rajoli; Manuel Battegay; Luigia Elzi; David Back; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

8.  Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions.

Authors:  Paul Hollywood; Rachel MacCann; David Lorigan; Eoghan de Barra; Samuel McConkey
Journal:  Ir J Med Sci       Date:  2019-11-18       Impact factor: 1.568

9.  Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.

Authors:  A K Pau; S D Boyd
Journal:  Clin Pharmacol Ther       Date:  2010-07-28       Impact factor: 6.875

10.  Effect of drug interactions involving antiretroviral drugs on viral load in HIV population.

Authors:  Carles Iniesta-Navalón; Juan José Franco-Miguel; Juan José Gascón-Cánovas; Lorena Rentero-Redondo
Journal:  Eur J Hosp Pharm       Date:  2015-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.